Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis

CompletedOBSERVATIONAL
Enrollment

111

Participants

Timeline

Start Date

March 7, 2017

Primary Completion Date

December 15, 2018

Study Completion Date

December 15, 2018

Conditions
Multiple Sclerosis
Interventions
DRUG

Fampridine

The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments and management of the disease will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behavior.

Trial Locations (1)

11528

Αiginitio hospital, Athens

All Listed Sponsors
lead

Genesis Pharma CNS & Specialty

INDUSTRY

NCT03164018 - Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis | Biotech Hunter | Biotech Hunter